Apr 23 |
ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications
|
Apr 23 |
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
|
Apr 23 |
Biggest stock movers today: GM, DHR, IBRX, NVS, and more
|
Apr 23 |
ImmunityBio stock jumps as FDA clears bladder cancer therapy
|
Apr 23 |
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
Apr 17 |
ImmunityBio files automatic mixed shelf
|
Mar 6 |
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
|
Mar 5 |
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
|
Feb 27 |
ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
|
Feb 21 |
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
|